Zoetis Inc. $ZTS Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 122,279 shares of the company’s stock after selling 12,923 shares during the period. Boston Trust Walden Corp’s holdings in Zoetis were worth $14,455,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Zoetis during the 4th quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis in the third quarter valued at approximately $31,000. Lodestone Wealth Management LLC purchased a new position in Zoetis in the fourth quarter worth approximately $30,000. Finally, Elyxium Wealth LLC purchased a new position in Zoetis in the fourth quarter worth approximately $32,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research analyst reports. TD Cowen reduced their target price on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. JPMorgan Chase & Co. cut their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Morgan Stanley restated an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. Finally, Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $126.92.

Insider Buying and Selling

In other Zoetis news, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 11,650 shares of company stock valued at $886,384 in the last ninety days. Company insiders own 0.22% of the company’s stock.

Zoetis Trading Down 0.1%

Shares of NYSE ZTS opened at $74.73 on Friday. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $161.77. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock has a fifty day simple moving average of $84.04 and a 200-day simple moving average of $109.40. The stock has a market capitalization of $31.33 billion, a PE ratio of 12.39, a PEG ratio of 1.17 and a beta of 0.75.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the company posted $1.48 EPS. Zoetis’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is presently 35.16%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.